The present technology relates to improvement of memory performance and the prevention or treatment of brain disorders associated with memory loss. In particular, the invention relates to the use of Centaurin-α1 (CentA1), CentA1 activating proteins, and CentA1 effector proteins as therapeutic targets to improve memory and cognitive performance in a normal subject and/or in a subject with neurological disorders associated with memory and/or cognitive impairments, such as Alzheimers disease.
